August 19, 2019 / 7:11 PM / a month ago

FDA approves Nabriva's antibiotic for pneumonia

Aug 19 2019 (Reuters) - The U.S. Food and Drug Administration on Monday approved Nabriva Therapeutics Plc’s antibiotic Xenleta for treating patients with community-acquired pneumonia.

The drug, also called lefamulin, works by interfering with the ability of bacteria to replicate and has been approved in both injectable and oral forms. (bit.ly/2ZhWqrH) (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Anil D'Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below